Menu
Menu
SOPHiA GENETICS is at the 17th Annual Meeting of the Cancer Genomics Consortium. Find us at Booth #29 to see how the SOPHiA DDM™ Platform is helping laboratories move from fragmented workflows to AI-driven, integrated, end-to-end solutions, able to generate actionable, evidence-based insights at scale.
Discover a platform built for the complexity of cancer genomics, across solid tumors and hematologic malignancies, driven by its global community and trusted by 990+ institutions across 75 countries.
Drop by our booth for an in-depth demo of our end-to-end applications:
Booth #29 hours:
Learn more:
Don't miss: 🎤 Science Café Presentation, Lizmery Ferguson Schires | Royal Sonesta Houston Galleria
Whether you're running a high-volume solid tumor program or building out comprehensive hemato-oncology capabilities, our team can show you how SOPHiA DDM™ streamlines the entire process, from concept to implementation.
Book 15 minutes with our team now or simply stop by our booth. See you in Houston.
Most lab leaders arrive at ADLM with the same question: how do we bring NGS in-house, or scale what we already run, without adding headcount, cost, or turnaround time?
At Booth #1172, the AVITI24 system and the SOPHiA DDM™ Platform’s AI-powered analysis run as one connected workflow. Your lab sequences and interprets its own data, and your data stays in-house.
780+ institutions run SOPHiA DDM™ today
70+ countries, standardizing and scaling NGS workflows
Stop by Booth #1172, wherever your lab is.
Tell us where you are, and we’ll tailor the conversation.
Booth #1172 hours:
Tue Jul 28, 9:30 AM–5:00 PM
Wed Jul 29, 9:30 AM–5:00 PM
Thu Jul 30, 9:30 AM–12:00 PM
See how to stand up sequencing and analysis together, without building a bioinformatics team from scratch.
See where SOPHiA DDM™ removes the bottlenecks you already feel: variant interpretation time, workflow standardization, and QC overhead.
Walk through the cost and turnaround math labs are using to build the business case for in-house testing.
Whether you’re evaluating NGS solutions, expanding your test menu, or exploring how AI can strengthen your genomic pipeline, our teams are ready to talk.
Book 15 minutes with our team now, or simply stop by and say hello. See you in Anaheim.
What began at our inaugural forum in 2024 has since taken shape across the field. SOPHiA GENETICS and the Memorial Sloan Kettering Cancer Center (MSK) return to ASCO to convene leading voices in precision oncology, this time with a singular focus: the liquid biopsy revolution.
This forum traces the journey from a pioneering academic-industry collaboration with MSK to a global movement reshaping how cancer is detected, monitored, and treated.
Topics:
Speakers:
Join SOPHiA GENETICS™ and ARC Regulatory for an exclusive Industry Reception bringing together precision medicine and pharma leaders in Boston on July 21st.
Following our recently announced Master Collaboration Agreement, this event will spotlight our integrated solution for pharma companies across the clinical development lifecycle in Europe, combining ARC's IVDR regulatory expertise with SOPHiA GENETICS' NGS technology and CE-IVD track record.
You’ll hear directly from both teams about key milestones, including the co-development of a Clinical Trial Assay (CTA) designed to accelerate patient recruitment in European clinical trials.
Accelerate with Impact: Expanding Patient Access to Precision Medicine Across the EU
The programme will be followed by a networking reception, offering a unique opportunity to connect with peers and leaders shaping the future of precision medicine.
Reserve your spot today!
We are thrilled to be back at 16th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub for the Next Generation of Precision Oncology
NEW YORK – June 4, 2026 – SOPHiA GENETICS (NASDAQ: SOPH) today announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint venture between the two institutions. The joint venture aims to build upon the strength of MSK innovation in clinical diagnostics and SOPHiA GENETICS’s Ai platform to potentially discover, develop, and deploy a new generation of precision oncology to patients around the world.
SOPHiA GENETICS and MSK bring unique strengths to the collaboration. SOPHiA DDM™, SOPHiA GENETICS's precision medicine platform, has been used to analyze more than 2.5 million cases since 2014, pioneering a unique, decentralized approach to precision oncology. MSK's in-house NGS program has sequenced more than 150,000 tumor samples since 2014, creating an extensive genomic dataset linked to clinical outcomes, pathology, and radiology records.
The MOU envisions a precision medicine hub that would combine MSK's clinical data and expertise with SOPHiA GENETICS’s Ai platform to unlock a new approach to multimodal precision oncology.
For patients, the proposed precision medicine hub will act as an incubation studio for the discoveries of tomorrow, equipped with a deployment platform to quickly deliver new capabilities to patients worldwide. The hub could move new discoveries from bench to clinical care faster than traditional models, expanding access to MSK’s oncology intelligence for patients across the globe.
For biopharma partners, the hub could provide dedicated infrastructure for next-generation companion diagnostics, clinical algorithm development, and evidence generation.
The two institutions have a history of successful collaboration. Through previous license agreements involving MSK assays such as MSK-IMPACT® and MSK-ACCESS®, SOPHiA GENETICS has brought MSK diagnostics innovation to hospitals, labs, and patients in 35 countries across the globe using its platform SOPHiA DDMTM.
Although the specifics of this strategic initiative have yet to be finalized, it is envisioned that SOPHiA DDM™ would serve as the Ai and analytics platform of the precision medicine hub, supporting its data, Ai, and bioinformatics needs. MSK would contribute its clinical and scientific leadership, including support from its oncology faculty and exceptional ability to generate high-quality clinical data.
SOPHiA GENETICS’s announcement of this Memorandum of Understanding comes at a pivotal moment in oncology, as interest in Ai-enabled precision medicine continues to grow. New targeted cancer therapies are pushing molecular diagnostics earlier in the treatment pathway, creating demand for new diagnostic capabilities and scalable testing platforms. At the same time, Ai is emerging as a critical tool for clinical decision-making, making the combination of clinical data and Ai infrastructure one of the field's most strategic capabilities.
Ross Muken, President, SOPHiA GENETICS, said: "Our work with MSK has always been about extending the reach of MSK’s clinical intelligence, and this joint venture is the most ambitious expression of that mission yet. Over the past several years, we’ve built SOPHiA DDM™ into a foundational Ai and analytics layer for precision medicine, helping institutions across the world unlock the value of their clinical data. By combining MSK's clinical leadership and deep clinical data with SOPHiA GENETICS's Ai platform and global infrastructure, the precision medicine hub that we are discussing will help move precision oncology into the multimodal era and bring the benefits of MSK’s precision oncology to patients regardless of where they're treated.”
Michael G. Frank, Director of Digital Health Business Development at MSK, said: "This collaboration represents the future of applied precision oncology – where clinical expertise meets cutting-edge Ai and robotics with the potential to transform cancer care at scale. By combining MSK's deep clinical assets with SOPHiA GENETICS's powerful digital platform, we're seeking to create a new paradigm to deliver personalized insights to patients.”
# # #
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is an Ai-native healthcare technology company on a mission to transform care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an Ai platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
San Diego, CA and New York, NY – April 16, 2026 – SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM™ Platform to advance cancer research and enhance genomic testing capabilities.
Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City, supports care for more than 4,000 oncology patients annually. Mount Sinai’s Molecular Pathology team will leverage SOPHiA DDM™ to strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors. The Platform is designed to enable detection and interpretation of a wide range of complex genomic variants while improving operational efficiency by consolidating critical steps in the analysis pipeline and reducing manual interpretation time.
By combining Mount Sinai’s clinical excellence with SOPHiA DDM™’s advanced AI-powered analytics, the hospital will be equipped to interpret complex genomic datasets at scale and optimize laboratory resources, enabling teams to focus on direct patient care.
Jane Houldsworth, Ph.D., Director of Molecular Oncology Pathology of the Mount Sinai Health System, said: “The collaboration between Mount Sinai and SOPHiA GENETICS reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care. Leveraging SOPHiA DDM™ has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care.”
John Carey, Managing Director, North America, SOPHiA GENETICS, said: “Mount Sinai is widely regarded as one of the world’s leading centers for cancer research and was recently ranked No. 1 globally among health care institutions in the Nature AI Index, underscoring its leadership in artificial intelligence and data-driven innovation. We are honored to support their teams with an AI-native platform and global network designed to deliver faster results, greater operational efficiency, and deeper genomic understanding to help shape the future of precision oncology.”
By utilizing the SOPHiA DDM™ for Blood Cancers and SOPHiA DDM™ for Solid Tumors applications, Mount Sinai joins a growing network of more than 990 global institutions using SOPHiA GENETICS’ decentralized platform to accelerate precision medicine. This collaboration underscores SOPHiA GENETICS’ mission to democratize data-driven medicine, delivering scalable, cloud-native solutions that empower healthcare institutions to expand access to advanced genomic testing and improve patient outcomes worldwide.
The collaboration was announced from the American Association for Cancer Research® (AACR) Annual Meeting in San Diego. Learn more by connecting with SOPHiA GENETICS at AACR booth #4248 from April 17 – 22, 2026.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com, or connect on LinkedIn.
About the Sumit
The decisions made in the next few years will define the trajectory of human health for decades to come. SOPHiA GENETICS brings together the pioneers making those decisions — clinicians, researchers, and biopharma leaders who refuse to accept the status quo.
Join us September 22–23, 2026 in Nashville for two immersive days at the intersection of AI, multimodal data, and precision medicine. Where bold ideas meet the real-world science to make them possible.
Travel & Accommodations
To make your visit to Nashville more convenient, we have secured a discounted room block at the Sheraton Grand Nashville Downtown, located just minutes from the event venue.
Sheraton Grand Nashville Downtown
623 Union St, Nashville, TN 37219
Special rate: $259/night plus applicable taxes and fees
Please note that attendance at the Innovation Summit, including the dinner and reception, is complimentary. Attendees are responsible for arranging and covering their own travel and accommodation expenses.
As a convenience for our guests, SOPHiA GENETICS has negotiated this discounted hotel rate; SOPHiA GENETICS does not receive any financial benefit from bookings made through this arrangement.
Reserve your room at the discounted rate here:
https://book.passkey.com/gt/221359136?gtid=40a8cc13a8d824c7aeca9c6b76c76932
Register your interest. Be part of what’s next.
The SOPHiA GENETICS™ Global Precision Medicine Forum returns to Chicago! Join us on May 29th at 3:00 PM CST at The Metropolitan in Chicago, IL, for its 2026 edition.
Two years ago, SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) started a liquid biopsy revolution that has since grown into a global shift in precision oncology access. This forum brings together the minds behind that shift to reflect on what was built, its real-world impact, and reveal what comes next.
Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From MSK to the World, and how it is reshaping the future of cancer care.
Across different sessions, the forum will explore:
Don't miss this unique opportunity and reserve your spot now!
SOPHiA GENETICS is thrilled to return for ACMG 2026! Visit us at booth #1007 to learn more about our SOPHiA DDM™ and Alamut™ Visual Plus platforms for rare and inherited diseases.
Discover more about our newly launched extended pharmacogenomics (PGx) application, which covers HLA and mitochrondrial regions, with dedicated analytical modules that call variants from SNVs and CNvs to star alleles and CYP2D6/CVP2D7 gene conversion.
Learn more about SOPHiA DDM™ for whole genome sequencing and how our enhanced exome solutions detect challenging variants relevant for carrier screening, hereditary cancer, and PGx in one comprehensive application.
Exhibit Theater 1
Thursday March 12
12:30pm-1:00pm
Future-Ready Genomics: Real World Implementation and Validation from Hereditary Cancer to WGS
Dr. Francisco Perez Blanco, PhD, Chief of Molecular Diagnostics and Biometrics Laboratory, Clinical Alemana de Santiago
Sevana Yaghoubian, MSc - Senior Director of Product Management, SOPHiA GENETICS.
Join this talk to hear real-world clinical experience, implementation, and validation insights, and performance data from SOPHiA DDM™ germline NGS applications, covering hereditary cancer, enhanced exomes, whole-genome sequencing, and pharmacogenomics.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.